Future Bright for EBOS Despite Setbacks
Future Bright for EBOS Despite Setbacks
On Wednesday, EBOS reported a 7.2% increase in statutory net profit after tax to NZ$271.5 million. Revenue grew by nearly 8% to NZ$13.2 billion, and EBOS Group (ASX:EBO), the New Zealand-based healthcare and pet products company, is moving forward with renewed confidence after a successful year. Despite a failed attempt to acquire Greencross in late 2023, EBOS has reported record sales and profits for the year ending June 30.
新西兰的医疗保健和宠物产品公司EBOS Group（ASX:EBO）在经历了一个成功的年度后，充满信心地迈进。尽管在2023年底未能成功收购Greencross，EBOS在截至6月30日的年度报告中报告了创纪录的销售额和利润。
The company's statutory net profit increased due to strong sales, which reached a new high of NZ$13 billion. However, this will be the last time EBOS reports such a large figure, as its supply deal with Chemists Warehouse ended on June 30. While the loss of this wholesale business will have an impact, the company expects minimal growth in earnings for the current financial year.
由于强劲的销售业绩，公司的法定净利润增加，达到了NZ$13亿的历史新高。然而，这将是EBOS最后一次报告这样庞大的数字，因为其与Chemists Warehouse的供应协议于6月30日结束。尽管失去这项批发业务将产生影响，但公司预计本财年盈利增长率较低。
EBOS operates in two main retail channels: supermarkets for pet care products and chemists and wholesalers for healthcare. Its most well-known healthcare businesses are Terry White Chemists and Symbion. The company's attempt to acquire Greencross was motivated by the loss of sales revenue to Chemists Warehouse.
EBOS在两个主要零售渠道运作：超市销售宠物护理产品，药房和批发商销售医疗保健产品。公司最知名的医疗保健业务是Terry White Chemists和Symbion。EBOS收购Greencross的举措是为了弥补因Chemists Warehouse的销售收入损失。
On Wednesday, EBOS reported a 7.2% increase in statutory net profit after tax to NZ$271.5 million. Revenue grew by nearly 8% to NZ$13.2 billion, and EBITDA increased by 6.5% to NZ$605.6 million. However, the company anticipates a decline in EBITDA due to the loss of the Chemists Warehouse supply deal.
EBOS在周三报告了法定税后净利润增长7.2％至NZ$2,715万元。收入增长近8％至NZ$13.2亿，EBITDA增长6.5％至NZ$6,056万元。然而，由于失去了与Chemists Warehouse的供应协议，公司预计EBITDA会下降。
The Christchurch-based company declared a final dividend of 61.5 NZ cents per share, bringing the total dividends to 118.5 NZ cents.
这家总部位于基督城的公司宣布每股支付61.5新西兰分的最终股息，使总股息达到118.5新西兰分。
EBOS attributed its record sales to growth in its community pharmacy and institutional healthcare divisions. The company highlighted strategic investments, including its stake in Transmedic, the acquisition of Superior Pet Food, and smaller acquisitions in medical technology and consumables.
EBOS将其创纪录的销售额归因于社区药房和医疗机构的增长。公司强调了战略性投资，包括其在Transmedic的股权，对Superior Pet Food的收购以及在医疗技术和消耗品领域的较小收购。
"The group's diversification is a key strength as we navigate challenging domestic economic conditions," said EBOS CEO John Cullity. "We have a strong pipeline of opportunities ahead as we continue to expand our operations outside New Zealand and Australia."
EBOS首席执行官John Cullity表示：“集团的多元化是我们在挑战性的国内经济环境中的一大优势。我们面前有一条强劲的机会管道，我们将继续扩大在新西兰和澳洲以外地区的业务。”
A significant factor for EBOS is the ongoing merger of Chemists Warehouse and Sigma Healthcare. The ACCC is likely to require the merged group to divest certain assets, particularly in wholesale and chemist retail outlets. This could present opportunities for EBOS to expand its businesses in Australia, potentially offsetting the loss of revenue from the Chemists Warehouse supply arrangement.
对EBOS来说，Chemists Warehouse与Sigma Healthcare的持续合并是一个重要因素。澳大利亚竞争与消费者委员会（ACCC）可能要求合并集团出售特定资产，尤其是批发和药房零售门店。这可能为EBOS在澳大利亚扩大业务提供机会，从而可能抵消Chemists Warehouse供应安排带来的收入损失。